Health and wellness company Perrigo Company plc (NYSE; TASE: PRGO) reported on Monday that it has received US Food and Drug Administration tentative approval for the generic version of Finacea Foam(azelaic acid) 15%.
The company added that it had announced a patent litigation suit with Bayer AG for the Finacea Foam (azelaic acid) 15%.
In conjunction with the patent litigation suit, LEO Pharma A/S acquired Finacea Foam (azelaic acid) 15% from Bayer AG and then substituted for Bayer AG as the lead plaintiff in the patent litigation suit concerning the product.
For the 12 months ending January 2019, the annual market sales were approximately USD62m as measured by IQVIA.
Teva Provides Update on Fremanezumab Clinical Development for Use in Episodic Cluster Headache
Teva Launches Generic Version of VESIcare Tablets in the United States
Teva Pharmaceutical begins US launch of generic VESIcare tablets
Oakrum Pharma signs product development and commercialisation partnership with Biophore
Teva Pharmaceutical launches generic version of VESIcare tablets in the US
Phyton Biotech and AqVida receive European approval for paclitaxel injectable FDF
The United States Food and Drug Administration approves Narcan
Teva Signs New USD 2.3bn Syndicated Revolving Credit Facility